-

Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.

The three-day event, in association with the London Stock Exchange, global law firm Taylor Wessing, and OpenExchange, will take place between January 25th-27th, focusing on 33 companies. Day one will feature businesses within pharmaceuticals & drug discovery, day two focuses on AI & technology in healthcare, while businesses adopting new approaches to hard-to-solve problems will round off the event.

Content will be available to stream from January 25th on Edison’s website and OpenExchange.tv. Attendance is free and anyone wanting to attend can sign up here: https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/

For more information on the event and details on how to register, please see below.

Edison Group:
Global Healthcare Open House Conference 2022
Date: January 25th-27th, 2022
Edison Group Open House Registration

Presentation information: The company presentation will be available on demand on www.edisongroup.com beginning at 7am ET on Wednesday, January 26th. The presentation will also be available on the Company’s investor relations page.

1x1 Meeting Registration: To register for a 1x1 meeting with the Company, please visit this link.

For any questions about the event or how to register, please reach out to openhouse@edisongroup.com

About Aditxt™

Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile. Aditxt’s immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile technology to equip people with information about their level of protection. For more information, please visit: www.aditxt.com and www.AditxtScore.com

About Edison Group:

Edison’s leading research and investor relations consultancy connects listed companies to the widest pool of global investors. By focusing on both the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors, Edison can create and gauge intent to purchase, even in the darkest pools of capital.
www.edisongroup.com

Contacts

Media and Investor Relations Contact:
Edison Investment Research
IR@aditxt.com

Industry:

Aditxt, Inc.

NASDAQ:ADTX
Release Versions
English

Contacts

Media and Investor Relations Contact:
Edison Investment Research
IR@aditxt.com

More News From Aditxt, Inc.

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and co...

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

GOLDEN, Colo.--(BUSINESS WIRE)--Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”) a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite’s CLIA-certified Reverse Phase Protein Array (“RPPA”) platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection. The initiative is expected to gener...

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics, LLC (“Ignite”) since March 2026, will now lead the full Ad...
Back to Newsroom